| アブストラクト | Background: Chronic kidney disease (CKD) is widely reported to decrease quality of life, increase morbidity and mortality and cause increased healthcare resource utilisation (HCRU) as the disease progresses. However, there is a relative paucity of accurate and recent estimates of HCRU in this patient population. Our aim was to address this evidence gap by reporting HCRU and related costs in patients with CKD from the UK primary and secondary care settings. Methods: HCRU and cost estimates of CKD were derived for UK patients included in the DISCOVER CKD cohort study using clinical records from the Clinical Practice Research Datalink linked to external databases. Patients with a history of transplant or undergoing dialysis were not included. HCRU and costs were stratified by CKD severity using the urinary albumin: creatinine ratio (UACR) and estimated glomerular filtration rate. Results: Hospitalisation rates more than tripled between low (A1) and high (A3) UACR categories and the mean annual per-patient costs ranged from pound4966 (A1) to pound9196 (A3) and from pound4997 (G2) to pound7595 (G5), demonstrating that a large healthcare burden can be attributed to a relatively small number of patients with later stage CKD, including those with kidney failure and/or albuminuria. Conclusions: HCRU and costs associated with CKD impose a substantial burden on the healthcare system, particularly in the more advanced stages of CKD. New interventions that can delay the progression of CKD to kidney failure may not only prolong the patient's life, but would also provide significant resource and cost savings to healthcare providers. |
|---|
| 投稿者 | Pollock, Carol; James, Glen; Garcia Sanchez, Juan Jose; Carrero, Juan Jesus; Arnold, Matthew; Lam, Carolyn S P; Chen, Hungta Tony; Nolan, Stephen; Pecoits-Filho, Roberto; Wheeler, David C |
|---|
| 組織名 | Kolling Institute, Royal North Shore Hospital University of Sydney, Sydney, NSW,;Australia.;BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.;Karolinska Institutet, Department of Medical Epidemiology and Biostatistics,;Stockholm, Sweden.;National Heart Centre, Department of Cardiology, Singapore, Singapore.;Duke-NUS Medical School, Singapore, Singapore.;AstraZeneca, Gaithersburg, MD, USA.;School of Medicine, Pontifical Catholic University of Parana, Curitiba, Brazil.;Arbor Research Collaborative for Health, Ann Arbor, MI, USA.;Department of renal medicine, University College London, London, UK. |
|---|
